NCT02882308 - Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

January 10, 2020

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Olaparib

50/25 mg BD split x 5 days

DRUG

Cisplatin

60 mg/m\^2 d1-d5

DRUG

Olaparib

300 mg BD x 21-28 days.

DRUG

Durvalumab

1500 mg d1

Trial Locations (2)

"University Hospital Attikon, 2nd Department of Internal Medicine, Division of Oncology", Athens

Euromedica General Clinic of Thessaloniki, Thessaloniki